-- AlphaValue/Baader Europe on Monday upgraded Swiss drugmaker Novartis (NOVN.SW) to add from reduce and lowered its price target to 131.00 francs from 134.00 francs.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)